Published: 6 January 2017
Author(s): Csaba András Dézsi, Balázs Bence Dézsi, Döme András Dézsi
Issue: January 2017
Section: Review Article

Coronary artery disease coexists in a clinically relevant number of patients with atrial fibrillation and it often requires percutaneous coronary intervention. These patients represent a particular challenge for clinicians in terms of antithrombotic management. They require combined antiplatelet–anticoagulant therapy to reduce the risk of recurrent ischemic cardiac events and stroke; however, this antithrombotic strategy is associated with an increased risk of bleeding complications. In the absence of randomized, controlled clinical trials, the majority of current recommendations rely on the results of cohort studies, meta-analyses, post-hoc analyses and subgroup analyses of large, phase III studies.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.